ZA947444B - Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide - Google Patents

Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Info

Publication number
ZA947444B
ZA947444B ZA947444A ZA947444A ZA947444B ZA 947444 B ZA947444 B ZA 947444B ZA 947444 A ZA947444 A ZA 947444A ZA 947444 A ZA947444 A ZA 947444A ZA 947444 B ZA947444 B ZA 947444B
Authority
ZA
South Africa
Prior art keywords
pyrrolidineacetamide
anxiety
oxo
alpha
ethyl
Prior art date
Application number
ZA947444A
Other languages
English (en)
Inventor
Ernst Wulfert
Jean Gobert
Alma Gower
Eric Cossement
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of ZA947444B publication Critical patent/ZA947444B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA947444A 1993-09-24 1994-09-23 Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide ZA947444B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939319732A GB9319732D0 (en) 1993-09-24 1993-09-24 Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety

Publications (1)

Publication Number Publication Date
ZA947444B true ZA947444B (en) 1995-05-11

Family

ID=10742476

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA947444A ZA947444B (en) 1993-09-24 1994-09-23 Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Country Status (17)

Country Link
US (1) US5447952A (cs)
EP (1) EP0645139B1 (cs)
JP (1) JP3688735B2 (cs)
KR (1) KR950007848A (cs)
AT (1) ATE191849T1 (cs)
AU (1) AU672334B2 (cs)
CA (1) CA2132509A1 (cs)
DE (1) DE69424009T2 (cs)
ES (1) ES2145818T3 (cs)
GB (1) GB9319732D0 (cs)
HU (1) HU217124B (cs)
NO (1) NO943521L (cs)
NZ (1) NZ264506A (cs)
RU (1) RU2142274C1 (cs)
SG (1) SG86284A1 (cs)
TW (1) TW283642B (cs)
ZA (1) ZA947444B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525347A (en) * 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
CA2392879C (en) 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
PL1810676T3 (pl) * 2006-01-24 2009-04-30 Teva Pharmaceutical Industries Ltd Formulacje lewetiracetamu i sposoby ich wytwarzania
CN101400348A (zh) * 2006-03-15 2009-04-01 埃科特莱茵药品有限公司 用于提高记忆功能的四氢异喹啉衍生物
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
PL2164847T3 (pl) * 2007-07-03 2012-02-29 Actelion Pharmaceuticals Ltd Związki 3-azabicyklo[3.3.0]oktanowe
WO2009016564A2 (en) * 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
ES2637497T3 (es) * 2008-10-16 2017-10-13 The Johns Hopkins University Procedimientos y composiciones para la mejora de la función cognitiva
US8191547B2 (en) * 2008-10-23 2012-06-05 S-2Tech Llc Portable solar-heating system having an inflatable solar collector
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
US20120214859A1 (en) * 2011-02-09 2012-08-23 Michela Gallagher Methods and compositions for improving cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
PH12021551305A1 (en) * 2018-12-04 2022-05-16 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1414845A1 (ru) * 1984-03-23 1988-08-07 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе 1-Тиокарбамоилметилпирролидин-2-тион,обладающий ноотропной активностью, и способ его получени
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
SU1320707A1 (ru) * 1985-01-24 1987-06-30 Ивано-Франковский Институт Нефти И Газа Способ определени износостойкости материалов ма тниковым склерометром
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP0408782A1 (en) * 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
CA2048003A1 (en) * 1990-08-21 1992-02-22 Serge Burner Tricyclic pyridone derivatives

Also Published As

Publication number Publication date
JP3688735B2 (ja) 2005-08-31
TW283642B (cs) 1996-08-21
EP0645139A1 (fr) 1995-03-29
ES2145818T3 (es) 2000-07-16
AU672334B2 (en) 1996-09-26
HU217124B (hu) 1999-11-29
HUT68299A (en) 1995-06-28
EP0645139B1 (fr) 2000-04-19
KR950007848A (ko) 1995-04-15
NO943521L (no) 1995-03-27
SG86284A1 (en) 2002-02-19
GB9319732D0 (en) 1993-11-10
NZ264506A (en) 1997-09-22
DE69424009D1 (de) 2000-05-25
DE69424009T2 (de) 2000-09-14
AU7416994A (en) 1995-04-06
CA2132509A1 (en) 1995-03-25
ATE191849T1 (de) 2000-05-15
RU2142274C1 (ru) 1999-12-10
US5447952A (en) 1995-09-05
JPH07149639A (ja) 1995-06-13
NO943521D0 (no) 1994-09-22

Similar Documents

Publication Publication Date Title
TW283642B (cs)
TW224942B (cs)
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
ZA925128B (en) Pyrrolidine derivatives,their preparation and medicaments containing them
DK0559413T3 (cs)
GB9514473D0 (en) Chemical compounds
GR3005470T3 (cs)
EP0455448A3 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
AU2806692A (en) Medicament for the treatment of anxiety
JPS6468368A (en) Use of 2-pyrimidinyl-1-piperazine derivative
GR3018674T3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
NO920984D0 (no) Fremgangsmaate for diastereoselektiv reduktiv pinakol-kobling av homokirale alfa-aminoaldehyder
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
EP0377127A3 (de) Verwendung von Myricetin-3-0-beta-D-glucuronid als Arzneimittel
IN172911B (cs)
CY2065B1 (en) Use of naphthoxazines
GR3003065T3 (en) Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility
ZA917001B (en) Medicaments containing substituted 2-cyclohexene derivates and their use for the control of diseases
EP0291888A3 (en) 4-substituted 1-cyanomethylene pyrroloû4,3-e¨-benzo-azepins
TW234715B (cs)
ZA937179B (en) Tetrahydorindazolone pharmaceutical compositions
ES2103166A1 (es) Procedimiento para la obtencion de amidinohidrazonas biciclicas.
ZA839573B (en) Novel 6alpha-methylprednisolone derivatives and their manufacture and use